Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Monday reported positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial evaluating Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) in previously untreated patients with PD-L1 positive metastatic triple-negative breast cancer.
Keytruda is owned by US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada.
The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to the current standard of care, Keytruda plus chemotherapy.
This marks the first pivotal Phase 3 trial to show superiority of a Trop-2-directed antibody-drug conjugate combined with immunotherapy in this setting.
An early trend toward overall survival improvement was also observed, although the data remain immature.
The safety profile of the Trodelvy-Keytruda combination was consistent with known profiles of each therapy, and no new safety signals emerged.
Trodelvy is the only approved Trop-2-directed antibody-drug conjugate with demonstrated survival benefits in multiple metastatic breast cancer indications.
The ASCENT-04 results support the potential of Trodelvy plus Keytruda as a new first-line treatment option for patients with PD-L1 positive locally advanced or metastatic triple-negative breast cancer.
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
S&E bio's SNE-101 stroke therapy approved for clinical trial
TransCode Therapeutics reports progress in metastatic cancer trial